Modulation of Cancer Networks through Protein Degradation, DNA Repair Inhibition, and Quantitative Interactomics

  • ACS Med Chem Lett. 2026 Feb 23;17(3):628-630. doi: 10.1021/acsmedchemlett.6c00082.
Anna C Renner  1 ,  Robert B Kargbo  2
Affiliations
  • 1. North Dakota State University, Fargo, North Dakota 58108-6050, United States.
  • 2. Independent Research Consultant, Middleton, Wisconsin 53562, United States.
PMID: 41847648 DOI: 10.1021/acsmedchemlett.6c00082
Abstract

Recent innovations in oncology drug discovery reveal a convergent strategy built on biological dependency, protein fate control, and quantitative network analysis. Epigenetic protein degradation enables durable transcriptional rewiring, helicase inhibition exploits synthetic-lethal DNA repair vulnerabilities, and DNA-barcoded interactomics quantifies higher-order protein complexes. Together, these advances redefine precision oncology as a system-level discipline driven by context, modality, and measurable biological consequence.

Products